Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
FAQ
- What is AbCellera Biologics Inc.'s D&A?
- AbCellera Biologics Inc. (ABCL) reported D&A of $6.99M in Q2 2026.
- How has AbCellera Biologics Inc.'s D&A changed year-over-year?
- AbCellera Biologics Inc.'s D&A increased by 27.8% year-over-year, from $5.47M to $6.99M.
- What is the long-term trend for AbCellera Biologics Inc.'s D&A?
- Over 2 years (2021 to 2023), AbCellera Biologics Inc.'s D&A has grown at a 29.9% compound annual growth rate (CAGR), from $14.45M to $24.4M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about AbCellera Biologics Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude